These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 11252546

  • 1. Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer. A cost-effectiveness analysis.
    Attanasio E, Russo P, Carunchio G, Caprino L.
    Pharmacoeconomics; 2001 Jan; 19(1):57-68. PubMed ID: 11252546
    [Abstract] [Full Text] [Related]

  • 2. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis.
    Gómez-Outes A, Rocha E, Martínez-González J, Kakkar VV.
    Pharmacoeconomics; 2006 Jan; 24(1):81-92. PubMed ID: 16445305
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
    Fowler RA, Mittmann N, Geerts W, Heels-Ansdell D, Gould MK, Guyatt G, Krahn M, Finfer S, Pinto R, Chan B, Ormanidhi O, Arabi Y, Qushmaq I, Rocha MG, Dodek P, McIntyre L, Hall R, Ferguson ND, Mehta S, Marshall JC, Doig CJ, Muscedere J, Jacka MJ, Klinger JR, Vlahakis N, Orford N, Seppelt I, Skrobik YK, Sud S, Cade JF, Cooper J, Cook D, Canadian Critical Care Trials Group, Australia and New Zealand Intensive Care Society Clinical Trials Group.
    JAMA; 2014 Nov 26; 312(20):2135-45. PubMed ID: 25362228
    [Abstract] [Full Text] [Related]

  • 4. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
    Lynd LD, Goeree R, Crowther MA, O'Brien BJ.
    Can J Clin Pharmacol; 2007 Nov 26; 14(2):e215-26. PubMed ID: 17652767
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P, De Groote K, Annemans L.
    Arch Orthop Trauma Surg; 2004 Oct 26; 124(8):507-17. PubMed ID: 15365714
    [Abstract] [Full Text] [Related]

  • 14. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T, Wolf H, Michaelis HC, Wagner W, Hoffmann A, Schmidt A, Beck H.
    Thromb Haemost; 1996 Feb 26; 75(2):246-50. PubMed ID: 8815569
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.
    Gould MK, Dembitzer AD, Sanders GD, Garber AM.
    Ann Intern Med; 1999 May 18; 130(10):789-99. PubMed ID: 10366368
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.